Hours | Speakers | Lecture title | Abstract | Number |
16:05 | Part 1 - Market analysis | 34776 | ||
16:05 | M&A dynamics and valuation trends in medical aesthetics | View | 31108 | |
16:15 | Global market analysis for aesthetic EBDs | 34792 | ||
16:25 | Global facial aesthetics: impacts of the illegitimate market | View | 34794 | |
16:35 | The digital consumer: challenges and opportunities | 34798 | ||
16:50 | Part 2 - Industry strategy | 34778 | ||
16:50 | Research and innovations as the driving force behind Galderma's product portfolio | 34800 | ||
17:00 | The new Allergan, leading the way in growth pharma | View | 34802 | |
17:10 | How does Merz cross-fertilize its Ulthera acquisition with its medical aesthetics division | 34804 | ||
17:20 | The role of EBDs in the global medical aesthetic market | 34806 | ||
17:40 | Part 3 - Round table on the laser, EBD & cosmeceutic markets | 34780 | ||
17:40 | Panel industry - Syneron | 34814 | ||
17:40 | Panel industry - Zeltiq | 37318 | ||
17:40 | Panel industry - Skinceuticals | 34816 | ||
17:40 | Panel industry - Thermi | 37976 | ||
17:40 | Panel industry - Filorga | 34808 | ||
18:10 | Part 4 - Round table on the injectable market | 34782 | ||
18:10 | Panel industry - Galderma | 34810 | ||
18:10 | Panel industry - Merz Pharma | 34746 | ||
18:10 | Panel industry - Vivacy Laboratories | 34744 | ||
18:10 | Panel industry - Allergan | 34812 | ||
18:10 | Panel industry - Croma Pharma | 38312 | ||
18:10 | Panel industry - Sinclair Pharma | 34738 | ||
18:10 | Panel industry - Teoxane Laboratories | 34796 | ||
18:50 | Questions & answers | 38314 | ||